期刊
BREAST
卷 24, 期 -, 页码 S36-S40出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2015.07.009
关键词
Chemotherapy; TNBCtype; Neoadjuvant; PIK3CA; Androgen receptor
资金
- National Cancer Institute [CA098131, CA68485]
- Komen for the Cure Foundation [SAC110030, CCR13262005]
Triple negative breast cancer (TNBC) is a molecularly heterogeneous disease lacking recurrent targetable alterations and thus therapeutic advances have been challenging. The absence of ER, PR and HER2 amplifications, leaves combination chemotherapy as the standard of care treatment option in the adjuvant, neoadjuvant and metastatic settings. Recently, multiple studies have shed some light on the heterogeneity of TNBC and identified distinct transcriptional subtypes with unique biologies. Herein we review the molecular heterogeneity and the impact on previous and future clinical trials. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据